• First clinical-grade transplant of gene-

    From ScienceDaily@1:317/3 to All on Thu Jan 20 21:30:48 2022
    First clinical-grade transplant of gene-edited pig kidneys into brain-
    dead human

    Date:
    January 20, 2022
    Source:
    University of Alabama at Birmingham
    Summary:
    Researchers have announced the first peer-reviewed research
    outlining the successful transplant of genetically modified,
    clinical-grade pig kidneys into a brain-dead human individual,
    replacing the recipient's native kidneys. These positive results
    demonstrate how xenotransplantation could address the worldwide
    organ shortage crisis.



    FULL STORY ==========================================================================
    The University of Alabama at Birmingham Marnix E. Heersink School of
    Medicine announces today the first peer-reviewed research outlining the successful transplant of genetically modified, clinical-grade pig kidneys
    into a brain- dead human individual, replacing the recipient's native
    kidneys. These positive results demonstrate how xenotransplantation
    could address the worldwide organ shortage crisis.


    ==========================================================================
    In the study published in the American Journal of Transplantation, UAB researchers tested the first human preclinical model for transplanting genetically modified pig kidneys into humans. The study recipient had two genetically modified pig kidneys transplanted in his abdomen after his
    native kidneys were removed. The organs were procured from a genetically modified pig at a pathogen-free facility.

    "Along with our partners, we have made significant investments in xenotransplantation for almost a decade hoping for the kinds of results published today," said Selwyn Vickers, M.D., dean of the UAB Heersink
    School of Medicine and CEO of the UAB Health System and UAB/Ascension
    St. Vincent's Alliance. "Today's results are a remarkable achievement
    for humanity and advance xenotransplant into the clinical realm. With
    this study, our research teams have also demonstrated that the decedent
    model has significant potential to propel the xenotransplantation field forward." For the first time, the pig kidneys transplanted were taken
    from pigs that had been genetically modified with 10 key gene edits
    that may make the kidneys suitable for transplant into humans. This
    process demonstrates the long-term viability of the procedure and how
    such a transplant might work in the real world. The transplanted kidneys filtered blood, produced urine and, importantly, were not immediately
    rejected. The kidneys remained viable until the study was ended, 77
    hours after transplant.

    "This game-changing moment in the history of medicine represents a
    paradigm shift and a major milestone in the field of xenotransplantation,
    which is arguably the best solution to the organ shortage crisis," said
    Jayme Locke, M.D., director of the Comprehensive Transplant Institute
    in UAB's Department of Surgery and lead surgeon for the study. "We have
    bridged critical knowledge gaps and obtained the safety and feasibility
    data necessary to begin a clinical trial in living humans with end-stage
    kidney failure disease." Gene editing in pigs to reduce immune rejection
    has made organ transplants from pigs to humans possible, which could
    offer help to thousands of people who face organ failure, disease or
    injury. The natural lifespan of a pig is 30 years, they are easily bred
    and can have organs of similar size to humans.



    ========================================================================== Genetically modified pig kidneys have been extensively tested in non-human primates. In addition to testing in non-human primates, evaluating
    genetically modified pig kidneys in a human preclinical model research
    may provide important information about the potential safety and efficacy
    of kidneys in human transplant recipients, including in clinical trials.

    "This human preclinical model is a way to evaluate the safety and
    feasibility of the pig-to-non-human primate model, without risk to a
    living human," Locke added. "Our study demonstrates that major barriers
    to human xenotransplantation have been surmounted, identifies where new knowledge is needed to optimize xenotransplantation outcomes in humans,
    and lays the foundation for the establishment of a novel preclinical human model for further study." This effort is supported by biotechnology
    pioneer United Therapeutics Corporation, which awarded a grant to UAB
    to launch the innovative xenotransplantation program. Revivicor, Inc.,
    a subsidiary of United Therapeutics, provided the genetically modified
    pig that was the source of the investigational xenotransplant kidneys
    called UKidney[TM].

    "All of us at Revivicor are in awe of the historic achievements at UAB
    with our investigational 10-gene xenokidney, or UKidney," said David
    Ayares, Ph.D., Chief Scientific Officer of Revivicor and a trailblazing
    genetic engineer since his early work cloning the world's first pigs
    and the first alpha-Gal knockout pigs. "We feel confident that this
    UKidney may turn out to be a life-saving solution for thousands of people
    on dialysis, subject to successful completion of our clinical trials
    and achievement of FDA approval in the next several years." About the
    study The peer-reviewed research is a study of ambitious scope and great significance, given that more than 800,000 Americans are living with
    kidney failure. Most never make it to the waiting list, and far too few
    human organs are available to put a dent in that number. Although dialysis
    can sustain life for some time, transplantation offers a better quality
    of life and a longer life for the few individuals who can gain access
    to transplantation. Each stage of this decedent xenotransplant study approximated the steps that might be taken in a Phase I xenotransplant
    clinical trial:
    * The kidneys were removed from a donor pig housed at a pathogen-free,
    surgically clean facility. The kidneys were then stored, transported
    and processed for implantation, just as human kidneys are.

    * Before surgery, the brain-dead recipient and donor animal
    underwent a
    crossmatch compatibility test to determine whether the genetically
    modified pig kidney and its intended recipient were a good tissue
    match.

    A crossmatch is done for every human-to-human kidney transplant;
    however, this pig-to-human tissue-match test was developed at
    UAB and marked the first time a prospective crossmatch has been
    validated between the two species.

    * The pig kidneys were placed in the exact anatomic locations used for
    human donor kidneys, with the same attachments to the renal artery,
    renal vein and the ureter that carries urine from the kidney to
    the bladder.

    * The brain-dead recipient received standard immune-suppression
    therapy
    used in human-to-human kidney allotransplantation.



    ==========================================================================
    The study was conducted to meet the standards directly comparable to
    those that would apply to a Phase I human clinical trial, mirroring every
    step of a standard transplant between humans. It included Institutional
    Review Board and Institutional Animal Care and Use Committee approval,
    a tissue compatibility confirmation before starting the operations,
    using the standard procedures of human-to-human transplants to remove, preserve, transport and transplant the kidneys into a human, and giving
    the standard immunosuppression therapy to the recipient.

    The critical need for other organ donation options Kidney disease kills
    more people each year than breast or prostate cancer, according to the
    National Institute of Diabetes and Digestive and Kidney Diseases. Although transplantation is the gold standard treatment for end-stage kidney
    disease, fewer than 25,000 kidney transplants are performed each year in
    the United States and 240 Americans on dialysis die every day. Many of
    these deaths could be prevented if an unlimited supply of kidneys were available for transplant.

    The wait for a deceased donor kidney can be as long as five years, and
    in many states, it is closer to 10 years. Almost 5,000 people per year
    die waiting on a kidney transplant.

    ========================================================================== Story Source: Materials provided by
    University_of_Alabama_at_Birmingham. Original written by Tyler
    Greer. Note: Content may be edited for style and length.


    ========================================================================== Related Multimedia:
    * YouTube_video:_Pig-to-human_kidney_transplant_3D_animation ========================================================================== Journal Reference:
    1. Paige M. Porrett, Babak J. Orandi, Vineeta Kumar, Julie Houp,
    Douglas
    Anderson, A. Cozette Killian, Vera Hauptfeld‐Dolejsek,
    Dominque E.

    Martin, Sara Macedon, Natalie Budd, Katherine L. Stegner, Amy
    Dandro, Maria Kokkinaki, Kasinath V. Kuravi, Rhiannon D. Reed,
    Huma Fatima, John T. Killian, Gavin Baker, Jackson Perry, Emma
    D. Wright, Matthew D.

    Cheung, Elise N. Erman, Karl Kraebber, Tracy Gamblin, Linda Guy,
    James F.

    George, David Ayares, Jayme E. Locke. First clinical‐grade
    porcine kidney xenotransplant using a human decedent model. American
    Journal of Transplantation, 2022; DOI: 10.1111/ajt.16930 ==========================================================================

    Link to news story: https://www.sciencedaily.com/releases/2022/01/220120091128.htm

    --- up 6 weeks, 5 days, 7 hours, 13 minutes
    * Origin: -=> Castle Rock BBS <=- Now Husky HPT Powered! (1:317/3)